J. William Harbour
- January 9, 2024
- Oncologist
Quick Facts
Full Name | J. William Harbour |
Occupation | Oncologist |
Date Of Birth | Jun 27, 1963(1963-06-27) |
Age | 61 |
Birthplace | Dallas |
Country | United States |
Birth City | Texas |
Horoscope | Cancer |
J. William Harbour Biography
Name | J. William Harbour |
Birthday | Jun 27 |
Birth Year | 1963 |
Place Of Birth | Dallas |
Home Town | Texas |
Birth Country | United States |
Birth Sign | Cancer |
J. William Harbour is one of the most popular and richest Oncologist who was born on June 27, 1963 in Dallas, Texas, United States.
When Harbour joined Washington University in 1996, he undertook a three-year postdoctoral research training program in molecular oncology, which resulted in a first author publication in the journal Cell showing that the retinoblastoma protein is regulated by successive phosphorylation events. This discovery was subsequently corroborated by protein crystallography and other lines of investigation and have helped to explain how some cancer cells inactivate the retinoblastoma protein by phosphorylation rather than mutation.
In the early 2000s, the focus of Harbour’s research turned to uveal melanoma, in which he discovered a gene expression profile that predicted with great accuracy which of these cancers would remain localized to the eye (class 1 profile) and which would metastasize (class 2 profile). Based on this discovery, his group developed a highly accurate clinical prognostic test with high technical performance and prognostic accuracy. The prognostic accuracy of the test was validated in the largest multicenter prospective validation study of its kind ever conducted in the field of ocular oncology. This study also demonstrated the prognostic superiority of the gene expression profile test over traditional clinical features used in the TNM classification, as well as chromosome 3 status, neither of which provided prognostic information that was independent of the gene expression profile test.
J. William Harbour Net Worth
Net Worth | $5 Million |
Source Of Income | Oncologist |
House | Living in own house. |
J. William Harbour is one of the richest Oncologist from United States. According to our analysis, Wikipedia, Forbes & Business Insider, J. William Harbour 's net worth $5 Million. (Last Update: December 11, 2023)
J. William Harbour, M.D., is a native of Dallas, Texas. He graduated from Hillcrest High School and earned his undergraduate degree in biochemistry at Texas A&M University where he graduated summa cum laude. Harbour then attended medical school at Johns Hopkins, where he developed a keen interest in interest in cancer biology. He completed medical school in 1990, followed by ophthalmology residency at the Wills Eye Hospital in Philadelphia, clinical fellowship in vitreoretinal diseases and surgery at the Bascom Palmer Eye Institute, and ocular oncology fellowship at the University of California, San Francisco.
Height, Weight & Body Measurements
J. William Harbour height Not available right now. Kamalesh weight Not Known & body measurements will update soon.
Who is J. William Harbour Dating?
According to our records, J. William Harbour is possibily single & has not been previously engaged. As of December 1, 2023, J. William Harbour’s is not dating anyone.
Relationships Record : We have no records of past relationships for J. William Harbour. You may help us to build the dating records for J. William Harbour!
In 2013, Harbour was first author on another landmark paper in the journal Nature Genetics describing frequent mutations in the splicing factor SF3B1 in uveal melanoma. Unlike BAP1, mutations in SF3B1 were associated with better clinical outcome.
Facts & Trivia
Kamalesh Ranked on the list of most popular Oncologist. Also ranked in the elit list of famous people born in United States. J. William Harbour celebrates birthday on June 27 of every year.
In 2016, the Harbour lab discovered that the cancer-testis antigen PRAME is yet another prognostic biomarker in uveal melanoma. Both class 1 and class 2 uveal melanomas expressing PRAME were shown to have a worse prognosis, but these tumors may also be subject to immunotherapy directed against PRAME.